Indeed, the advent of novel monoclonal/bsAb formats and combination strategies point towards the clear potential for increased tumour selectivity and efficacy and reduced toxicity of CD47‐SIRPα‐based immunotherapy. This evidence concerns the gene SIRPA and neoplasm.